Skip to content
value.today

Lipocine Inc.

PharmaceuticalsFounded 2011
Total raised
$38 M
1 round on record
Latest round
$38 M
Jul 2013
First round on record
Jul 2013
Today
Went public
See the company page

Lipocine Inc. is listed today as Lipocine Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Lipocine Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2013$38 MNo. 1$10 to $50 million

Lipocine Inc.: Raise no. 1, Jul 2013

Investors in this round

27 investors had bought by the notice of Aug 5, 2013: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$38 M of $38 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,900,999
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gerald K. Simmons · Executive Officer
  • Mahesh V. Patel · Executive Officer, Director
  • Robert K. Merrell · Executive Officer
  • Srinivasan K. Venkateshwaran · Executive Officer
  • Gordhan K. Patel · Director
  • John W. Higuchi · Director
  • William I. Higuchi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ladenburg Thalmann & Co., Inc. (CRD 505) · broker-dealer Ladenburg Thalmann & Co., Inc. (CRD 505) · New York, New YorkSold in CA, CO, MA, NJ, NY, TX

Remarks in the notice

  • On fees: “5% of gross proceeds.”

Signed by Mahesh V. Patel, Ceo. Source: SEC Form D, newest notice filed Aug 5, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Lipocine Inc., its revenue in fiscal 2025 came from these product and service lines: License $1.50 million (76%), Royalty $480,000 (24%).

    Annual report (SEC XBRL) · Dec 2025

  • Lipocine Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2013).

    SEC Form D · Aug 2013

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2013

Products and services#

No products or services of Lipocine Inc. are on record.

Investors#

No investor of Lipocine Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 27 investors.

Largest shareholders today

Institutions holding Lipocine Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Lipocine Inc.
NameRoleNamed in
Gerald K. SimmonsExecutive officerAug 2013
Mahesh V. PatelExecutive officerAug 2013
Robert K. MerrellExecutive officerAug 2013
Srinivasan K. VenkateshwaranExecutive officerAug 2013
Gordhan K. PatelDirectorAug 2013
John W. HiguchiDirectorAug 2013
Mahesh V. PatelDirectorAug 2013
William I. HiguchiDirectorAug 2013

Went public since 2013. Its SEC number is that of a company listed on a stock exchange.